These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26623270)

  • 41. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management.
    Carr RM; Oranu A; Khungar V
    Gastroenterol Clin North Am; 2016 Dec; 45(4):639-652. PubMed ID: 27837778
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nonalcoholic Steatohepatitis: A Review.
    Sheka AC; Adeyi O; Thompson J; Hameed B; Crawford PA; Ikramuddin S
    JAMA; 2020 Mar; 323(12):1175-1183. PubMed ID: 32207804
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [An interpretation of the AASLD practice guideline on the diagnosis and management of nonalcoholic fatty liver disease in 2017].
    Nan YM; Fu N; Li WC; Kong LL; Yuan XW; Zhang SY; Liu LD; Lu Y; Cui LY
    Zhonghua Gan Zang Bing Za Zhi; 2017 Sep; 25(9):687-694. PubMed ID: 29108191
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics.
    Polyzos SA; Kountouras J; Mantzoros CS
    Metabolism; 2019 Mar; 92():82-97. PubMed ID: 30502373
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of surgically induced weight loss on nonalcoholic fatty liver disease in morbidly obese Indians: "NASHOST" prospective observational trial.
    Praveen Raj P; Gomes RM; Kumar S; Senthilnathan P; Karthikeyan P; Shankar A; Palanivelu C
    Surg Obes Relat Dis; 2015; 11(6):1315-22. PubMed ID: 26003897
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treating nonalcoholic fatty liver disease.
    Méndez-Sánchez N; Arrese M; Zamora-Valdés D; Uribe M
    Liver Int; 2007 Nov; 27(9):1157-65. PubMed ID: 17919226
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease.
    Chen G; Ni Y; Nagata N; Xu L; Ota T
    Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27563875
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
    Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
    Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diagnostic and Treatment Implications of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Wong T; Wong RJ; Gish RG
    Gastroenterol Hepatol (N Y); 2019 Feb; 15(2):83-89. PubMed ID: 31011302
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD.
    Hossain N; Kanwar P; Mohanty SR
    Gastroenterol Res Pract; 2016; 2016():7109270. PubMed ID: 27006654
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of bariatric surgery on outcomes of patients with nonalcoholic fatty liver disease: a nationwide inpatient sample analysis, 2004-2012.
    McCarty TR; Echouffo-Tcheugui JB; Lange A; Haque L; Njei B
    Surg Obes Relat Dis; 2018 Jan; 14(1):74-80. PubMed ID: 29055669
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Non-alcoholic fatty liver disease: The diagnosis and management.
    Abd El-Kader SM; El-Den Ashmawy EM
    World J Hepatol; 2015 Apr; 7(6):846-58. PubMed ID: 25937862
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nonalcoholic Fatty Liver Disease and Obesity Treatment.
    Brunner KT; Henneberg CJ; Wilechansky RM; Long MT
    Curr Obes Rep; 2019 Sep; 8(3):220-228. PubMed ID: 30945129
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nonalcoholic fatty liver disease (NAFLD): a comprehensive review.
    Salt WB
    J Insur Med; 2004; 36(1):27-41. PubMed ID: 15104027
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metabolic Syndrome: Nonalcoholic Fatty Liver Disease.
    Williams T
    FP Essent; 2015 Aug; 435():24-9. PubMed ID: 26280342
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?
    Budd J; Cusi K
    Am J Med; 2020 May; 133(5):536-543. PubMed ID: 32017891
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular pathways of nonalcoholic fatty liver disease development and progression.
    Bessone F; Razori MV; Roma MG
    Cell Mol Life Sci; 2019 Jan; 76(1):99-128. PubMed ID: 30343320
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Younossi ZM; Loomba R; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Chalasani NP; Anstee QM; Kowdley KV; George J; Goodman ZD; Lindor K
    Hepatology; 2018 Jul; 68(1):361-371. PubMed ID: 29222911
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome.
    Aguilar-Olivos NE; Almeda-Valdes P; Aguilar-Salinas CA; Uribe M; Méndez-Sánchez N
    Metabolism; 2016 Aug; 65(8):1196-207. PubMed ID: 26435078
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.
    Satapathy SK; Sanyal AJ
    Semin Liver Dis; 2015 Aug; 35(3):221-35. PubMed ID: 26378640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.